ASCO 2016 abstract 1

Population pharmacokinetics of PQR309, a dual PI3K/mTOR inhibitor in adult patients with advanced solid tumors. Matthias Machacek1, Lionel Renaud1, Sasa Dimitrijevic2, Debora Schmitz2, Elena Ivanova2, Karin Jorga3; 1LYO-X GmbH, Allschwil, Switzerland; 2PIQUR Therapeutics AG, Basel, Switzerland; 3Karin Jorga Life Science Consulting GmbH, Basel, Switzerland. J Clin Oncol 34, 2016 (suppl; abstr e14101).